e nature of basophil activation as an ex vivo challenge makes it a multifaceted and promising tool for the allergist.
Abstract
e nature of basophil activation as an ex vivo challenge makes it a multifaceted and promising tool for the allergist. rough the development of ow cytometry, discovery of activation markers such as CD63 and markers identifying basophil granulocytes, the basophil activation test (BAT) has become a pervasive test. BAT measures basophil response to allergen crosslinking IgE on between 150 and 2,000 basophil granulocytes with remarkable analytical sensitivity in < 0.1 ml fresh blood. Dichotomous activation is assessed as the fraction of reacting basophils. In patients with food-, insect venom-, and drug allergy and patients with chronic urticaria BAT can be part of the diagnostic evaluation in addition to history, skin prick testing, and speci c IgE determination. BAT may also be helpful in determining the clinically relevant allergen. Basophil sensitivity may be used to monitor patients on allergen immunotherapy, anti-IgE treatment, or in the natural resolution of allergy. e test may use fewer resources and be more reproducible than oral, sting, nasal or bronchial challenge testing. BAT may be useful before challenge testing as it is less stressful for the patient and avoids severe allergic reactions. It may be useful before challenge testing. An important next step is to standardize BAT and make it available in diagnostic laboratories. is article provides an overview of the practical and technical details as well as the utility of BAT in diagnosis and management of allergic diseases.
Introduction
e clinical impact of the basophil activation test (BAT) is due to the unique ability of basophils to degranulate upon cross-linking of the speci c IgE (sIgE) bound on membrane-bound high a nity IgE-receptor (FcεRI) by allergen exposure. A er discovery of the quantal upregulation of CD63 during basophil activation in 1991 [1] , the BAT was developed in the 1990s [2] . CD63 is a membrane protein localized to the same secretory lysosomal granule that contains histamine. Translocation of CD63 to the cell membrane during degranulation can be measured by ow cytometry. BAT (like skin prick test, SPT) re ects a functional response as basophil (or skin mast cell) activation can be induced by cross-linking of FcεRI.
In this article -adapted from the EAACI Task force position paper [3] -we provide an overview of the practical and technical details as well as the utility of BAT in diagnosis and management of allergic diseases.
Blood samples for BAT
Antihistamines do not interfere with BAT, but systemic steroids and cyclosporin A should be avoided [4, 5] . It is recommended to take blood samples within 1 year of the most recent exposure to the allergen source [6, 7] . Blood samples can be used within 24 hours [8] , even though basophils may lose reactivity. As there is diurnal variation in the reactivity to CD203c [9] , timing of blood sampling may be important. Tests carried out with whole blood are most commonly utilized. Separation of cells from protective elements found in plasma may optimize activation through cell-bound sIgE.
Interleukin-3 (IL-3) enhances kinetics, reactance, and sensitivity of blood basophils to FcεRI-mediated activation independently of extracellular calcium. It also enhances the allergen speci c up-regulation of CD63 [4, 10] , but unspeci cally upregulates CD203c [11] .
Selection of the source of allergen extracts
e allergen selecting procedure is listed in Fig 1. e optimized concentrations for a wide range of allergens, allergen sources, and allergen extracts are listed in the original position paper in table S1 [3] . Furthermore, optimized allergen preparations are available from vendors. Drug aller gens are typically active in the mg/mL range and can be diluted 5-to 25-fold. If possible, pure active ingredients or injectable intravenous drug preparations should be used since solubilized tablets are complex mixtures of drugs and excipients.
Protein allergens are o en used in concentrations starting in the µg/mL range, and may be diluted up to 5-15 log concentrations to ng/mL -pg/mL before loss of reactivity. If recombinant allergen preparation or puri ed allergens are used for BAT, the molar concentration of allergens enables very precise analyses.
is standardized allergen preparation is essential when comparing basophil sensitivity data.
Flow cytometry in BAT
At present, BAT with CD63 is the best clinically validated test [12, 13, 14] , but the test based on CD203c has been shown to be a reliable test [15, 16] .
Basophils can be identi ed with di erent combinations of antibodies in ow cytometry. ey were rst identi ed as circulating IgE + cells. However, low side scatter in combination with CD123 + /HLADR -, CRTH2 + , CD203c + , or CD193 + are commonly applied combinations. Cell surface expression of the If possible, perform a pricktest or determine sIgE. Sensitizing allergen might be replaced by analogous allergen.
In case of a response to allergen, attempt to identify individual sensitizing molecules to predict cross-reactions and determine sensitizing agents by establishing sensitization to allergen molecules.
If the allergen is not available as standardized reagent, prepare a standardized crude extract: Blend 10 g allergen in 100 ml PBS to homogeneity Centrifuge 15 ml at 600 g and 4 °C for 8 min Use allergen extract at 10 %, 1 % and 0.1 % In case of a positive result, include 1-3 controls Use standardized allergen reagent if available.
Allergo J Int 2016; 25: 106-13 basophil selection marker CD193 (CCR3) was more stable than IgE or CD123/HLA-DR on resting basophils [17] . IgE and CD123/HLA-DR showed somewhat more inter-individual variability in cell surface expression. CD203c can be used both for identi cation and as an activation marker. Quality of blood basophils obtained is usually con rmed by stimulation with the bacterial peptide fMLP. Anti-IgE or anti-FcεRI antibodies are used as IgE-mediated positive controls, bu er as negative control.
If standardized commercial tests are not utilized, the method used for testing has to undergo validation.
Presentation and interpretation of BAT
ere are two common measures of basophil activity: basophil reactivity [2] , the number of basophils that respond to a given stimulus, and basophil sensitivity [1, 18] , the allergen concentration at which half of all reactive basophils respond (Fig. 2a) . Basophil reactivity depends on the priming state of the basophil and the cellular translation of the IgE signal within the cell [19] . It is su cient to measure reactivity at one or two concentrations and assessment of basophil reactivity is important using a positive control before baso phil sensitivity to allergen is measured.
Basophil sensitivity is a function of reactivity and the compound a nity of cell-bound sIgE for allergen and free competing immunoglobulin. It requires measurement of reactivity at 6-8 allergen concentrations. e graded response to allergen is tted to a curve of reactivity vs. allergen concentration, and the eliciting concentration at which 50 % of basophils respond (EC50) is determined (Fig. 2b) . EC50 can be expressed as "CD-sens" by inversion and multiplication by 100 [20] .
More recently, the area under the dose curve (AUC) measurement attempts to combine reactivity and sensitivity into one (Fig. 2c) ; it is similar to a coordinate system of sensitivity and reactivity, but also incorporates partial anergy induced at high allergen concentrations and can be calculated even in cases where responses do not t well to a typical dose-response curve [21] . ROC curves are used in identi cation of novel allergens when ≥ 7 sensitized patients are available.
Basophil granulocytes of non-responders (6-17 % of population) can remain unresponsive to stimulation through FcεRI. It is attributed to di erences in the intracellular signaling pathway. Results from non-responder patients should be regarded as false negatives.
Placing BAT in the diagnostic algorithm for allergic disease
In the general algorithm for diagnosis of allergy (Fig 3, Fig 4) , patient history should be taken with (20) with permission from the authors. a: Basophil reactivity is the dose (range) at which maximal response occurs. Basophil sensitivity is the dose at which half of the maximal response occurs. *At high allergen concentrations, basophil response may be suppressed. b: A change in sensitivity toward higher allergen concentration is the most reproducible basophil biomarker for reduced clinical sensitivity to allergen to date. Attempts to reduce the number of basophil activation tests required to determine a signi cant change in basophil response have focused on identifying an allergen concentration at which a change in sensitivity can readily be assessed (grey box). c: Basophil response could also be assessed as area under the curve (AUC) with a log allergen axis, or a similar composite measure re ecting both reactivity and sensitivity. Variation in maximal basophil reactivity arises concurrently with, and may be inseparable from, a change in sensitivity. an attempt to identify the allergen source and assess the severity of the allergic reaction. e allergic response should be con rmed by measurement of sIgE, skin prick testing, and, for insect venom and drug allergy, intradermal testing. Measurement of sIgE may not be possible if the allergen source is not available as a routine reagent, and may be of limited value depending on the performance of the available reagents. BAT is a functional test resembling an ex vivo IgE-mediated cellular response. It can be measured at the same time as sIgE, and in general precedes in vivo provocation tests.
Chronic urticaria e mechanism of chronic spontaneous urticaria (CU) is still incompletely understood. About half of the patients have autoantibodies against FcεRI and a few against IgE. CU sera activate resting basophils of normal donors to upregulate CD63 and CD203c. BAT may replace the autologous serum skin test (ASST) [22] .
BAT with CD63 upregulation as an activation marker for CU was established as a speci c, sensitive, and safe in vitro alternative to detect functional autoantibodies [10, 23, 24] . e central problem is the heterogeneity of the results using di erent basophil donors. is can be normalized by titrated addition of IL-3 [10] . BAT with autologous basophils should not be performed because CU patients are o en non-responders or poor responders to IgE crosslinking and have diagnostic basopenia.
Key messages
-BAT may replace ASST as the standard diagnostic procedure to identify autoreactive serum factors in CU with a quanti able result that may be used to monitor treatment. -BAT removes the risk of accidental infection.
-In contrast to ASST, there is no need to suspend antihistamines, as they do not in uence the result of BAT.
Drug allergy
e diagnostic work-up of drug hypersensitivity reactions (DHR) aims to identify the culprit agent, to identify cross-reactive drugs, and to determine a safe alternative drug [25] . Here, BAT is an additional tool that is safer, gentler, and cheaper than a challenge and, in some instances, is the only available diagnostic tool. e sensitivity of BAT in diagnosis of drug allergy is about 50 %, the speci city up to 93 %.
ere are several studies including BAT in drug allergy diagnosis for beta-lactams, neuromuscular blocking agents (NMBA), quinolones, radio contrast media, and pyrazolones with good sensitivity and speci city.
BAT provides positive results in 40 % of the patients with immediate-type systemic reaction and negative skin test and con rmed by provocation that constitute about 25 % of all beta-lactam-allergic patients. BAT has also a good negative predictive value, useful in the decision to perform the provocation test as demonstrated with quinolones. Furthermore, it has a complementary role to skin tests for di erent drug hypersensitivities and can be particularly useful in the study of cross-reactivity between NMBA, for the identi cation of safe alternatives for future surgery [25, 26] . Food allergy e performance of BAT in the diagnosis of food allergies has been assessed in various studies. e reported sensitivity of BAT ranges from 77-98 %, and the speci city from 75-100 %. In these studies, BAT was more accurate than sSPT and sIgE [27, 28] . For single individuals BAT sensitivity seems to allow a risk estimation for severe clinical reactions: In peanut allergy, BAT signi cantly improved clinical diagnosis over the use of SPT and sIgE and reduced the number of oral food challenges (OFC) required. BAT showed 100 % speci city, suggesting that in patients with a positive BAT the OFC could be deferred [29] .
Patients with clinical allergy that developed symptoms in an OFC to peanut had high basophil sensitivity to peanut, and patients who tolerated peanuts in an OFC had low basophil sensitivity to peanut. Although both OFC and basophil sensitivity identi ed all clinically sensitized children, only basophil sensitivity was reproducible at two consecutive visits (r 2 = 0.94). In a recent publication, BAT reactivity re ected the allergy severity and BAT sensitivity re ected the threshold of response to the allergen source in an OFC [30] .
It has been shown that basophil reactivity distinguish patients that tolerate extensively heated forms of cow's milk and egg from patients who do not. BAT may be useful in assessing the natural resolution of food allergies that are commonly outgrown over time, such as cow's milk allergy [28] and in determining when the food can safely be reintroduced in the diet. BAT has also been used to monitor clinical response to immune-modulatory treatment of food allergy.
Basophil CD203c expression has shown to decrease during treatment with Omalizumab and to return to pre-treatment levels a er cessation of therapy in patients with peanut allergy [31] . Also, improvement in basophil sensitivity to milk of milk allergic children treated with Omalizumab predicted tolerance in a milk challenge test.
Key messages
-BAT can improve the diagnosis of food allergy in addition to SPT and sIgE and may be able to reduce the number of OFC.
-BAT can be used to monitor the natural resolution and clinical response to immune-modulatory treatments for food allergy.
Hymenoptera venom allergy
Overall, the diagnostic sensitivity of BAT with insect venoms referred to the history was found to be 85-100 %, the diagnostic speci city 83-100 % [13, 14, 15] . Speci c diagnostic problems can be resolved by measuring basophil reactivity and sensitivity. BAT in patients with negative standard tests: A subset of patients (4-6 %) with a history of systemic reactions a er Hymenoptera stings have negative venom-speci c IgE and skin test results. BAT allows the identi cation of about two-thirds of those patients [32] .
BAT in patients sensitized to bee and wasp venom double "positivity": Up to 60 % of the patients with Hymenoptera venom allergy have sIgE to both bee and wasp venom. Basophil reactivity has the lowest rate of double positivity of diagnostic tests for Hymenoptera allergy [33] and repeatedly shows a positive result to only one venom in about one-quarter to one-third of patients with double sIgE positivity [13, 34] . In the case of patients with double positive BAT, the venom to which the patient is markedly more sensitive might represent the primary sensitizing allergen source, but this requires further research. BAT adds more clinically relevant information about the culprit insect than component-resolved sIgE testing with single recombinant allergens [32, 34] . However, recombinant venom allergens applied to BAT might represent a step forward in developing better in vitro tests for speci c diagnosis of Hymenoptera allergy.
Monitoring the e ect of venom immunotherapy with basophil sensitivity: A clear decrease in basophil sensitivity is found up to 4 years a er initiation of venom immunotherapy (VIT) , without a change in basophil reactivity. A recent report about an 8-year follow up of patients submitted to VIT showed that the decrease in basophil sensitivity seemed to be also associated with the induction of tolerance [35] . Some studies suggest that side e ects during the build-up phase of VIT are predicted by a high basophil sensitivity [36] .
Key messages
-Basophil reactivity and sensitivity (in that order)
play an important role in the diagnosis of venom allergy, as they are e ective tools to identify the primary sensitizing antigen. -e utility of basophil sensitivity as the tool of choice to monitor the e ect of VIT should be explored.
Inhalant allergens
Determination of sIgE or skin testing in combination with the clinical history are usually su cient to diagnose allergy to inhalant allergens. However, in speci c cases BAT can be helpful for diagnosis.
Patients with local allergic rhinitis by nasal provocation who have no detectable sIgE or skin testing but have a positive BAT are a notable example [37] .
Crude allergen sources as well as modi ed and recombinant allergens have been tested with good outcomes, basophil sensitivity correlates with the nasal provocation titer in allergic rhinitis [38] , the allergen speci c bronchial provocation threshold in allergic asthma, and the asthma control test. is indicates that basophil allergen threshold sensitivity (CD-sens or EC50) may accurately re ect clinical allergen sensitivity [39] .
Monitoring the e ect of allergen immunotherapy and anti-IgE treatment e ect: Basophil sensitivity can be used to assess the e cacy of allergen-speci c immunotherapy (AIT) to aeroallergens. It has been used to monitor patients treated with AIT for birch and timothy [18, 19] and showed reduced allergen sensitivity already during the up-dosing stage. Baso phil sensitivity has also successfully been used to identify patients who respond to the humanized monoclonal anti-IgE antibody Omalizumab and to assess treatment e cacy [40] .
Key messages
-Basophil sensitivity has the unique ability to monitor a patient's inhalant allergen sensitivity over time, to measure natural progression of allergy, and may be developed to serve as a tool to measure the response to treatment with AIT and Omalizumab.
Perspectives
Di erent methods of reporting results of BAT may be useful when asking di erent clinical questions; stimulation index and % positive basophils are used. When reactivity is measured in clinical settings, the aim is usually to identify an allergen concentration at which change in sensitivity is optimally identied. Basophil sensitivity is used to monitor change in allergic disease. Both reactivity and allergen sensitivity are measured when allergy severity is evaluated by basophil sensitivity, but a useful composite measure has yet to be designed.
A threshold for basophil reactivity is o en set at 2 %, 10 %, or 15 % of resting basophils. An alternative method would be to set the threshold halfway between the MFI of resting basophils and the positive control.
Major applications of BAT are summarized in Tab. 1. Laboratory procedures and allergen concentrations in BAT should be standardized, e. g., with the use of industry standards like MiFlowCyt or purchase of standardized material from CE-approved vendors. An important next step is the standardization and automation of analysis of BAT.
en it will be possible to perform large multicenter trials to characterize the diagnostic performance of BAT and broaden its use as a clinical tool. Such studies should also address the relationship of measures of BAT and sensitivity to sIgE, clinical symptoms and symptom severity. 
